This article is more than 5 years old. Information may no longer be current.
Cipla launches salmeterol/fluticasone metered-dose inhaler in Germany, Sweden
Click Here to Manage Email Alerts
Cipla has launched its salmeterol/fluticasone metered-dose inhaler in Germany and Sweden, according to a press release.
The product will be branded as Serroflo in Germany and Salmeterol/Fluticasone Cipla in Sweden and will be available in a pressurized metered-dose inhaler with hydrofluoroalkane propellant in two strengths, 120 doses at 25/125 mcg salmeterol/fluticasone and 120 doses of 25/250 mcg salmeterol/fluticasone, the release said.
Croatia is the only other European country where the combination currently is available.
“Over the next 12 to 18 months, we will see a series of launches throughout Europe as we know that there is a common need for high-quality, affordable, reliable and thus sustainable therapy alternatives,” Subhanu Saxena, managing director and global chief executive officer of Cipla, said in the release.
The launch “is a key milestone in Cipla’s ambition to improve treatment adherence in asthma and to offer better health care solutions for patients irrespective of what disease they suffer from,” the release said. “Over 50% of patients with asthma in Europe have suboptimal control and [the product] will provide a new cost-efficient option for many people with asthma.”